Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, multi-center, open label, dose escalation, safety, pharmacokinetic, and pharmacodynamic study of orally administered SGX523, a small molecule anti-cancer agent, on a twice daily, interrupted schedule in patients with advanced cancer

Next Previous
X
Search
Trial Profile

A phase I, multi-center, open label, dose escalation, safety, pharmacokinetic, and pharmacodynamic study of orally administered SGX523, a small molecule anti-cancer agent, on a twice daily, interrupted schedule in patients with advanced cancer

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2008

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SGX 523 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors SGX Pharmaceuticals

    • Most Recent Events

    • 22 Jul 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Mar 2008 Dose limiting toxicity was observed earlier than anticipated; no patients are currently being treated in the interrupted dose trial.
    • 21 Jan 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top